复方阿嗪米特肠溶片联合复合营养素(Noveliver)对失代偿期肝硬化患者血清白蛋白及前白蛋白水平的影响  

Effect of compound azintamide entericcoated tablet combined with compound nutrients(Noveliver) on serum albumin and pre-albumin levels in patients with decompensated liver cirrhosis

作　　者：杨雅阁 张孟徐[2] 郑晓永 李鸿彬 白阳秋[3] 杨玉秀[3] 张炳勇[3] 

机构地区：[1]河南省直第三人民医院消化内科,河南省郑州市450052 [2]郑州大学第三附属医院小儿消化内科,河南省郑州市450052 [3]郑州大学人民医院消化内科,河南省郑州市450003

出　　处：《世界华人消化杂志》2015年第10期1644-1648,共5页World Chinese Journal of Digestology

基　　金：河南省卫生厅医学科技攻关基金资助项目;No.2011020122~~

摘　　要：目的:观察联合应用复方阿嗪米特肠溶片和复合营养素(Noveliver),对失代偿期肝硬化患者血清白蛋白(albumin,ALB)、前白蛋白(pre-albumin,PA)水平及腹水的发生情况和严重程度的影响.方法:共有35例失代偿期肝硬化纳入研究,包括20例治疗组患者接受复方阿嗪米特肠溶片联合复合营养素(Noveliver)治疗加常规药物治疗,15例只接受常规药物治疗.随访12 wk,随访期限内,收集两组患者腹水的发生情况及严重程度;检测两组患者血清ALB及PA水平.结果:在治疗后12 wk,复方阿嗪米特肠溶片联合复合营养素(Noveliver)治疗组腹水改善情况显著优于对照组(P<0.05).治疗组血清PA及ALB水平逐渐增加,其中血清PA水平在治疗后4 wk时(110.3 mg/L±14.6mg/L vs 100.8 mg/L±7.5 mg/L,P<0.05)、ALB在治疗后8 wk时(31.9 g/L±2.5 g/L vs29.8 g/L±2.1 g/L,P<0.05)即显著高于对照组,两组差异有统计学意义(P<0.05),并持续至12 wk.结论:复方阿嗪米特肠溶片联合复合营养素(Noveliver)改善失代偿期肝硬化患者的营养状况,提高血清ALB及PA的水平,改善腹水的发生情况及严重程度.AIM：To observe the effect of compotind azintamide enteric-coated tablet combined with compound nutrients（Noveliver） on serum albumin（ALB）and pre-albumin（PA） levels in patients with decompensated liver cirrhosis.METHODS：A total of 35 inpatients with decompensated liver cirrhosis were enrolled in this trial,including 20 patients treated with compound azintamide enteric-coated tablet combined with compound nutrients（Noveliver）plus routine medical treatment,and 15 patients receiving routine medical treatment only as controls.The efficacy of compound azintamide enteric-coated tablet combined with compound nutrients（Noveliver） was monitored during a12-week follow-up period.RESULTS：After treatment with compound azintamide enteric-coated tablet combined with compound nutrients（Noveliver）,serum PA and ALB levels increased gradually.PA levels at 4 wk after treatment were 110.3 mg/L ± 14.6mg/L vs 100.8 mg/L ± 7.5 mg/L（P 〈0.05） in the treatment group and control group.ALB levels at 8 wk after treatment and 31.9 g/L ± 2.5 g/L vs 29.8 g/L ± 2.1 g/L（P 〈0.05） in the treatment group and control group.The efficacy continued to 12 wk after treatment.CONCLUSION：Compound azintamide enteric-coated tablet combined with compound nutrients（Noveliver） improves the nutritional status of patients with decompensated cirrhosis,increases serum ALB and PA levels,and reduces the incidence and severity of ascites.

关 键 词：复方阿嗪米特肠溶片 复合营养素 失代偿期肝硬化 血清白蛋白 血清前白蛋白 

分 类 号：R575.2[医药卫生—消化系统]